https://scholars.lib.ntu.edu.tw/handle/123456789/588130
標題: | An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC | 作者: | Zhu, Viola W YEN-TING LIN Kim, Dong-Wan Loong, Herbert H Nagasaka, Misako To, Hao Ang, Yvonne Li-En Ock, Chan-Young Tchekmedyian, Nishan Ou, Sai-Hong Ignatius Syn, Nicholas L Reungwetwattana, Thanyanan CHIA-CHI LIN Soo, Ross A |
關鍵字: | ALK; Expanded access; Lorlatinib; NSCLC; ROS1; TKI-refractory | 公開日期: | 2020 | 卷: | 15 | 期: | 9 | 來源出版物: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 摘要: | Lorlatinib, a next-generation central nervous system-penetrant ALK/ROS1 tyrosine kinase inhibitor (TKI), is approved to treat TKI-refractory ALK-positive (ALK+) NSCLC based on results from a phase 2 study. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/588130 | ISSN: | 15560864 | DOI: | 10.1016/j.jtho.2020.04.019 | SDG/關鍵字: | alanine aminotransferase; anaplastic lymphoma kinase; ceritinib; crizotinib; lorlatinib; protein tyrosine kinase; protein tyrosine kinase inhibitor; receptor tyrosine kinase 1; unclassified drug; lorlatinib; macrocyclic lactam; oncoprotein; protein kinase inhibitor; protein tyrosine kinase; ROS1 protein, human; adult; aged; ALK gene; Article; blurred vision; body weight disorder; brain metastasis; carcinomatous meningitis; clinical trial; cognitive defect; cohort analysis; constipation; depression; dizziness; drug efficacy; drug response; drug safety; dry eye; edema; enzyme activity; fatigue; female; gait disorder; genetic analysis; hallucination; hemorrhoid; human; hypercholesterolemia; hypertransaminasemia; hypertriglyceridemia; major clinical study; male; median survival time; multicenter study; myalgia; non small cell lung cancer; peripheral neuropathy; pneumonia; priority journal; progression free survival; rash; ROS1 gene; side effect; treatment duration; tumor-related gene; genetics; Hong Kong; lung tumor; South Korea; Taiwan; Hong Kong; Humans; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Republic of Korea; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。